The State of Texas has opened applications for $350 million in advanced nuclear grants through the Texas Advanced Nuclear Development Fund (TANDF), making the nation’s largest state‑level nuclear ...
Hosted on MSN
Oklahoma lawmakers advance bills on free speech, data centers, and summer feeding programs
Oklahoma lawmakers advance bills on free speech, data centers, and summer feeding programs Pope delivers holy warning to Trump in blistering address Wild video shows chaos in LA after 'No Kings' ...
The company’s portfolio includes two programs: OKI-345 for breast cancer and OKI-355 for vascular anomalies. OnKure plans to submit Investigational New Drug applications to the U.S. Food and Drug ...
Master advanced skills in regulatory communications with a focus on strategy, storytelling, and executive presence. This program combines live virtual sessions and practical exercises, empowering ...
Broadband industry leader Zenita Henderson to align marketing, sales, and partner programs, accelerating AMT’s role in nationwide broadband expansion DEERFIELD ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose ...
· Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged’ with special proteins Project awarded up to $41.3m by ...
ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially ...
RENO, Nev., April 01, 2026 (GLOBE NEWSWIRE) -- Eagle Nuclear Energy Corp. (“Eagle” or the “Company”) (NASDAQ: NUCL), a next-generation nuclear energy company which owns the largest conventional, ...
ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EU C-Further Consortium collaboration adds to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results